Lung
Lung carcinoma
Bronchogenic carcinoma, among the most common primary malignancies: squamous and small cell carcinomas usually arise centrally near the hilum, adenocarcinomas and large cell carcinomas usually in the periphery. Explore a real patient’s CT with a 3 cm lung nodule outlined by radiologists.
Causes et facteurs de risque
- Cigarette smoking: inhaled carcinogens such as benzo(a)pyrene drive stepwise mutations (for example TP53 and KRAS)
- Radiation, and occupational exposures such as silica (silicosis roughly doubles the risk)
- Adenocarcinoma is the type that occurs more often in non-smokers and former smokers
Aspect macroscopique
- Central tumours (squamous, small cell) arise near the hilum and can obstruct a main bronchus, collapsing the lung beyond (atelectasis) and causing pneumonia.
- Peripheral tumours (adenocarcinoma, large cell) form a mass away from the hilum; a solitary mass suggests a primary tumour rather than a metastasis.
- Squamous cell carcinoma is very firm, with a pale white to tan cut surface; small cell carcinoma is soft and lobulated and spreads widely.
- Adenocarcinoma in situ can resemble pneumonic consolidation rather than a discrete mass.
Au microscope
- Squamous cell carcinoma: pink keratinised cytoplasm, distinct cell borders and intercellular bridges; preceded by squamous metaplasia, dysplasia and carcinoma in situ.
- Adenocarcinoma: glandular structures, sometimes with mucin droplets; in situ forms grow along the alveolar walls (lepidic growth).
- Small cell carcinoma: sheets of small dark cells with scant cytoplasm and crush artefact; a neuroendocrine tumour (chromogranin, synaptophysin).
- Large cell carcinoma: poorly differentiated, without glandular or squamous features; a diagnosis of exclusion.
Évolution
- Carcinogens in smoke cause mutations in the bronchial lining; the epithelium undergoes squamous metaplasia, then dysplasia.
- Carcinoma in situ develops: full-thickness dysplasia that has not yet breached the basement membrane.
- Invasive carcinoma forms a mass, centrally obstructing an airway or peripherally as a nodule.
- It spreads to the hilar lymph nodes and mediastinum; small cell carcinoma often metastasises widely while the primary is still small.
Complications
- Airway obstruction with atelectasis and post-obstructive pneumonia
- Invasion of the mediastinum and hilar lymph nodes
- Paraneoplastic syndromes: hypercalcaemia from parathormone-related peptide (squamous); Cushing syndrome and inappropriate ADH with hyponatraemia (small cell); Lambert-Eaton myasthenic syndrome
Examens complémentaires
- Chest radiograph
- A mass, an enlarged hilum, collapse of a lobe beyond an obstructed bronchus, or a pleural effusion.
- CT of the chest and upper abdomen
- The size of the tumour, nodes and metastases (liver, adrenals); used for staging.
- Tissue diagnosis
- Bronchoscopic or CT-guided biopsy, endobronchial ultrasound sampling of nodes, or sputum cytology.
- Molecular testing
- In adenocarcinoma: EGFR mutations, ALK rearrangements and other alterations.
- Calcium and sodium
- Hypercalcaemia (squamous carcinoma) or hyponatraemia from inappropriate ADH (small cell carcinoma).
Traitement médicamenteux
- Platinum compounds (cisplatin, carboplatin, oxaliplatin): Cytotoxic drugs that cross-link DNA; the backbone of chemotherapy for lung, testicular, gastric and colorectal cancers and osteosarcoma. Each has its own toxicity: cisplatin the kidney and ear, carboplatin the marrow, oxaliplatin the nerves.
- Microtubule inhibitors (vinca alkaloids and taxanes): Drugs that disrupt the mitotic spindle so cells cannot divide: vinca alkaloids stop microtubules forming, taxanes stop them breaking down. Used in lymphomas, breast and lung cancer; neuropathy is the shared toxicity.
- Topoisomerase inhibitors (etoposide, irinotecan): Drugs that trap DNA-cutting enzymes on DNA: etoposide (topoisomerase II) in testicular tumours and small cell lung cancer; irinotecan (topoisomerase I) in colorectal cancer.
- Immune checkpoint inhibitors: Antibodies that release the brakes on T cells (PD-1, PD-L1, CTLA-4) so the immune system attacks the tumour; they transformed melanoma, renal cell, lung and liver cancer and Hodgkin lymphoma, but can trigger autoimmune damage to any organ.
- EGFR tyrosine kinase inhibitors: Targeted drugs that block the epidermal growth factor receptor kinase; highly effective in lung adenocarcinomas carrying activating EGFR mutations, which is why tumours are tested before treatment.
Anatomie concernée
Sujets liés
Rédigé d’après
- Robbins and Cotran Atlas of Pathology, 3rd ed., Ch. 5, The Lung, pp. 143–151, figs 5-98 to 5-124
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.